Latest Breaking News On - Reshma kewalramani - Page 19 : comparemela.com

Vertex Announces US FDA Approval of CASGEVY™ (exagamglogene autotemcel) for the Treatment of Transfusion-Dependent Beta Thalassemia

- Approximately 1,000 patients in the U.S. 12 years of age and older are now eligible for this one-time treatment - .

City ofUnited kingdomUnited statesReshma kewalramaniCompanies to workVertex pharmaceuticals incorporated nasdaqExchange commissionDrug administrationVertex pharmaceuticals incorporatedChief executive officerTransfusion dependent beta thalassemiaVertex connectsCare managersPrescribing informationPatient informationNorth america

Casgevy cleared for second rare blood disorder

About five weeks after the Food and Drug Administration greenlighted Casgevy as a breakthrough treatment for sickle cell disease, the agency cleared it for a related condition: transfusion-dependent beta thalassemia.

United statesUnited kingdomReshma kewalramaniInstitute for clinicalNobel prizeEconomic review

CRISPR/Vertex gene editing drug cleared for beta-thalassemia

CRISPR/Vertex gene editing drug cleared for beta-thalassemia
seekingalpha.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from seekingalpha.com Daily Mail and Mail on Sunday newspapers.

United statesReshma kewalramaniVertex pharmaceuticalsBoston children

Vertex Pharma (VRTX) Announces US FDA Approval of CASGEVY for Treatment of Transfusion-Dependent Beta Thalassemia

Vertex Pharma (VRTX) Announces US FDA Approval of CASGEVY for Treatment of Transfusion-Dependent Beta Thalassemia
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Reshma kewalramaniDrug administrationVertex pharmaceuticals incorporated nasdaqVertex pharmaceuticals incorporatedChief executive officerTransfusion dependent beta thalassemiaVertex connectsCare managers

FDA Approves New CRISPR Gene-Editing Treatment

The Food and Drug Administration approved the use of Casgevy, a CRISPR gene-editing therapy, for treating the serious blood disorder transfusion-dependent beta thalassemia the second major approval for the emerging therapy.

Reshma kewalramaniEmmanuelle charpentierJennifer doudnaVertex pharmaceuticalsDrug administrationNobel prizeCrispr therapeutics